Who was studied?
Participants received weekly retatrutide or placebo while on stable background diabetes treatment. The study ran across eight countries.
- Participants
- 1,152 adults
- Duration
- 80 weeks
- Funding
- Eli Lilly
What did the study find?
The treatment-regimen analysis reported average weight reduction of 18.8% at 12 mg versus 5.1% with placebo at week 80, alongside improved glycemic control.
What should you keep in mind?
Gastrointestinal events, hypotension and altered skin sensation were more frequent with retatrutide. Discontinuations due to adverse events or death were 8% at 12 mg versus 5% with placebo.
Why it matters
Different populations and analysis methods prevent a direct ranking against TRIUMPH-1 or other compounds.
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a phase 3 trial
Published 2026 · PMID 42810372 · DOI 10.1016/S0140-6736(26)01861-1
Summary by Peptide Lit, checked against the original abstract on October 7, 2026. Read the complete paper for detailed methods and safety results. This page explains published research; it does not recommend a treatment or dose.